Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China

Objective This study aimed to investigate the type and frequency of mutations in 10 genes in 85 colorectal cancer (CRC) patients in Huizhou and the guiding significance of targeted drug use. Methods The 10-gene panel next-generation sequencing (NGS) was used to assess genetic variants in 85 CRC pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jun Li, Aihua Sun, Guofang Zhong, Ying He, Hailin Xiong, Xia Yuan
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b58dfca97c9b4e18a5401bad9c7298e4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b58dfca97c9b4e18a5401bad9c7298e4
record_format	dspace
spelling	oai:doaj.org-article:b58dfca97c9b4e18a5401bad9c7298e42021-12-02T08:04:44ZMutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China1473-230010.1177/03000605211061040https://doaj.org/article/b58dfca97c9b4e18a5401bad9c7298e42021-11-01T00:00:00Zhttps://doi.org/10.1177/03000605211061040https://doaj.org/toc/1473-2300Objective This study aimed to investigate the type and frequency of mutations in 10 genes in 85 colorectal cancer (CRC) patients in Huizhou and the guiding significance of targeted drug use. Methods The 10-gene panel next-generation sequencing (NGS) was used to assess genetic variants in 85 CRC patients from the Huizhou area combined with clinical information for a comprehensive analysis. Results Upon initial mutation testing, 68% (58/85) were positive. The mutation frequencies of these genes, including KRAS, PIK3CA, NRAS, ERBB2, BRAF, EGFR, and PDGFRA , were 51%, 20%, 5%, 4%, 4%, 1%, and 1%, respectively. Overall, 29 mutation types were detected from seven genes. More mutations were detected in more advanced cancers. There were three samples with multiple mutations of a single gene, including KRAS (n = 2) and ERBB2 (n = 2), 12 samples with multiple mutations of double genes, including KRAS/PIK3CA (n = 10), BRAF/PIK3CA (n = 1), and NRAS/PIK3CA (n = 1), and one sample with multiple mutations of three genes, including ERBB2/KRAS/PIK3CA (n = 1). Theoretically, 27 patients could receive targeted treatment. During the actual treatment, 10 patients received bevacizumab, cetuximab, or fruquintinib with no progression ranging from 12 to 24 months. Conclusion Gene mutations detected by a 10-gene panel were useful for targeting therapy of CRC in Huizhou.Jun LiAihua SunGuofang ZhongYing HeHailin XiongXia YuanSAGE PublishingarticleMedicine (General)R5-920ENJournal of International Medical Research, Vol 49 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jun Li Aihua Sun Guofang Zhong Ying He Hailin Xiong Xia Yuan Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China
description	Objective This study aimed to investigate the type and frequency of mutations in 10 genes in 85 colorectal cancer (CRC) patients in Huizhou and the guiding significance of targeted drug use. Methods The 10-gene panel next-generation sequencing (NGS) was used to assess genetic variants in 85 CRC patients from the Huizhou area combined with clinical information for a comprehensive analysis. Results Upon initial mutation testing, 68% (58/85) were positive. The mutation frequencies of these genes, including KRAS, PIK3CA, NRAS, ERBB2, BRAF, EGFR, and PDGFRA , were 51%, 20%, 5%, 4%, 4%, 1%, and 1%, respectively. Overall, 29 mutation types were detected from seven genes. More mutations were detected in more advanced cancers. There were three samples with multiple mutations of a single gene, including KRAS (n = 2) and ERBB2 (n = 2), 12 samples with multiple mutations of double genes, including KRAS/PIK3CA (n = 10), BRAF/PIK3CA (n = 1), and NRAS/PIK3CA (n = 1), and one sample with multiple mutations of three genes, including ERBB2/KRAS/PIK3CA (n = 1). Theoretically, 27 patients could receive targeted treatment. During the actual treatment, 10 patients received bevacizumab, cetuximab, or fruquintinib with no progression ranging from 12 to 24 months. Conclusion Gene mutations detected by a 10-gene panel were useful for targeting therapy of CRC in Huizhou.
format	article
author	Jun Li Aihua Sun Guofang Zhong Ying He Hailin Xiong Xia Yuan
author_facet	Jun Li Aihua Sun Guofang Zhong Ying He Hailin Xiong Xia Yuan
author_sort	Jun Li
title	Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China
title_short	Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China
title_full	Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China
title_fullStr	Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China
title_full_unstemmed	Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China
title_sort	mutation analysis of a 10-gene panel for colorectal cancer in huizhou, guangdong province of china
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/b58dfca97c9b4e18a5401bad9c7298e4
work_keys_str_mv	AT junli mutationanalysisofa10genepanelforcolorectalcancerinhuizhouguangdongprovinceofchina AT aihuasun mutationanalysisofa10genepanelforcolorectalcancerinhuizhouguangdongprovinceofchina AT guofangzhong mutationanalysisofa10genepanelforcolorectalcancerinhuizhouguangdongprovinceofchina AT yinghe mutationanalysisofa10genepanelforcolorectalcancerinhuizhouguangdongprovinceofchina AT hailinxiong mutationanalysisofa10genepanelforcolorectalcancerinhuizhouguangdongprovinceofchina AT xiayuan mutationanalysisofa10genepanelforcolorectalcancerinhuizhouguangdongprovinceofchina
_version_	1718398682024378368

Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China

Ejemplares similares